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Low rates of compliance with medication pose a major challenge to the effective management of most chronic 
diseases, including asthma. The high medical and social costs of non-compliance, and the apparent lack of effective 
methods for dealing with it, has stimulated renewed interest in this complex issue. Two broad categories of non- 
compliance have been identified, namely unintentional (or ‘accidental’) and intentional (or ‘deliberate’). 
Unintentional non-compliance may result from poor doctor-patient communication or a lack of ability to follow 
advice. Intentional non-compliance occurs when the patient knows what is required but decides not to follow this to 
some degree. Healthcare professionals need to be aware of the various issues affecting compliance in all patients. 
The reasons for non-compliance are many and varied, and include factors such as complexity of the treatment 
regimen, administration route, patient beliefs about therapy and other psychological factors. Improvement in 
patient compliance with therapy will require better doctor-patient communication, improved patient education, the 
tailoring of therapy to the individual and possible novel strategies such as offering feedback to the patients on their 
level of compliance. 
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Introduction 
Compliance with medical regimens has been reported to be 
a major problem facing medical practice, and it has been 
suggested that only about 50% of patients with chronic 
diseases take their medicines at therapeutically effective 
doses (1). For example, patients who failed to adhere to 
their treatment regimen after a myocardial infarction were 
2.6 times more likely to die within 1 yr of follow-up than 
those adhering to treatment (2). Also, it has been suggested 
that the most common cause of kidney transplant failure is 
a failure to take immunosuppressive drugs (3). Similar 
findings have been reported for many other chronic 
diseases, including hypertension (4), childhood leukaemia 
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(5), insulin-dependent diabetes (6) and asthma (7). Many 
efforts have been made to improve patient compliance, but 
there is little evidence of sustained success (8). 
Compliance might be considered to be the interface 
between effective therapy and effective disease manage- 
ment. For example, the most effective asthma drug will be 
useless unless patients take it in sufficient amounts to 
control their disease. Non-compliance is not simply caused 
by a lack of knowledge on the part of the patient, and 
increasing patient knowledge alone is insufficient to 
improve compliance. 
Types of non-compliance 
Non-compliance with therapy can take many forms and 
can be the result of very different underlying causes. 
Identifying the reasons for non-compliance is essential for 
determining the appropriate intervention strategy (9). Two 
broad categories of non-compliance have been identified, 
namely unintentional (or ‘unwitting’) and intentional (or 
‘intelligent’) non-compliance. 
UNINTENTIONAL NON-COMPLIANCE 
Patients who are unintentional non-compliers are unaware 
that they are not complying. Reasons for unintentional 
non-compliance include misunderstanding the regimen, 
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incorrect device technique and language barriers. This type 
of non-compliance can often be missed at clinic visits. 
Studies examining doctor-patient communication have 
shown that after a consultation up to 50% of patients 
cannot accurately recount what they are supposed to do 
(10,ll). 
INTENTIONAL NON-COMPLIANCE 
In intentional non-compliance there is a conscious decision 
by the patient to reject, to some degree, either the diagnosis 
or the treatment. This type of non-compliance often takes 
the form of patients reducing the frequency of dosing or the 
number of medications to the level that they believe is 
necessary or appropriate, but some patients may discon- 
tinue therapies that they believe are ineffective, unnecessary 
or dangerous. 
In addition, erratic compliance may occur in some 
patients in each of these two categories. These patients 
know when and how to take their medication, but still fail 
to comply. Thus, intentional non-compliance may be 
erratic, and in some patients, unintentional non-compliance 
may result from forgetfulness, stress and being too busy. 
Erratic non-compliance may be more common with difficult 
or complex regimens that require interruptions of daily 
activities. Hence, effective interventions for addressing this 
might include simplifying the regimen, behavioural strate- 
gies such as ‘cues’ (e.g. reminder notes), and ‘self-monitor- 
ing’ (e.g. asthma diaries). 
Methods of assessing patient 
compliance 
A range of different methods have been used to assess 
compliance, each having various advantages and disadvan- 
tages (Table 1) (7). The simplest method is patient self- 
reporting, which is easy for the patient to perform but is 
sometimes inaccurate and may provide an over-estimation 
of compliance. These over-estimations may reflect patient 
forgetfulness, a bias toward remembering compliant days 
rather than non-compliant days, or a desire to please the 
clinician (i.e. social desirability). The validity and reliability 
of self-report measures can be enhanced by diminishing the 
social pressure on patients to under-report non-adherence 
by phrasing adherence questions in a non-threatening 
manner and assuring them that responses are anonymous 
and confidential as recommended in the literature (12). Self- 
report questionnaires have been validated by comparing 
adherence with tablet-count (13) and clinical outcome 
measures (14). Thus, although self-reporting does not 
provide an exact measure of when and how patients took 
their medication, it may be used to grade patients according 
to their relative standing on the adherence dimension (15). 
It produces an ordinal rather than an interval scale of 
assessment. 
The accuracy of clinicians’ impressions of compliance has 
been shown to vary widely in chronic disease, even if a 
clinician’s judgement is fast and inexpensive. Similar to self- 
reporting, the use of written or electronic diary cards for 
patients with asthma to record their symptom score and 
lung function (measured with a peak flow meter at home) 
may be used to assess compliance in patients with asthma. 
However, this method may be inaccurate as a result of copy 
errors or mistimed entries, and compliance may be over- 
estimated because of deliberate retrospective false entries by 
patients made in order to please the clinician (16,17). 
‘Pill counting’, or the weighing of inhalers in the case of 
asthma treatment, is a more objective means of assessment; 
however, it is only of limited value in intentional non- 
compliance because it is unable to distinguish between 
correct use of the drug and the deliberate emptying of 
medication prior to a scheduled visit to the doctor or clinic 
TABLE 1. Methods used for assessing compliance (adapted with permission (7)) 
Method Advantage Disadvantage 
Clinician’s judgement 
Patient self-reporting 




Drug level monitoring 
Fast, low cost 
Ease of use, fast, low cost 
Ease of use, fast 
Objective, simple, low cost 
Accurate, objective 
Accurate 
Unreliable, not valid by itself 
Inaccurate, may overestimate 
compliance 
Inaccurate, poorly completed, 
vulnerable to patient adherence 
Does not differentiate true use 
from ‘dumping’; time and staff 
consuming 
Can identify ‘dumping’ but this 
cannot indicate if a patient 
actually received dose 
Limited availability, expensive, 
insensitive for inhaled agents, 
invasive 
(drug ‘dumping’). Similar problems exist with medication 
monitoring devices such as microprocessor-based pill 
dispensers or disc puncture counters. Furthermore, a record 
of the correct number of tablets, or device actuations, at the 
appropriate time does not necessarily indicate that the 
patient is taking the medication correctly. The use of 
electronic monitoring devices may generate more accurate 
records but the electronic device itself may introduce bias if 
it alters the appearance and functionality of the inhaler. An 
accurate method of confirming drug use and dosage is drug 
level monitoring. However, it is costly, invasive, the 
availability of assays is limited, and local application of a 
drug may lead to low systemic levels that may be difficult to 
detect (7). 
Patient compliance with asthma 
therapy 
National and international guidelines, based on evidence 
from clinical studies, have suggested that long-term inhaler 
therapy using inhaled steroids and inhaled &agonists is the 
most appropriate strategy for the management of asthma. 
However, poor compliance with regular long-term inhaled 
medication is a significant issue among patients with 
asthma and can result in increased morbidity and mortality 
(18-20). Despite the importance of assessing compliance in 
asthma patients, the number of published studies is limited. 
Examination of a cross-section of the published studies 
evaluating compliance in asthma patients indicates that 
these studies used a variety of different methods, used 
objective and/or subjective measures of compliance and 
evaluated different routes of administration (Table 2) (21- 
28). These studies showed that compliance was achieved in 
466196% of patients, obviously leading to a variety of 
different conclusions. 
Overall, it is clear that there are considerable variations 
in the reported level of compliance with asthma medication 
since it is affected by many factors. It is also apparent that 
compliance with treatment is frequently not optimal and 
that patients’ perceived (reported) compliance is consider- 
ably greater than their actual (recorded) compliance. 
Factors affecting compliance with 
asthma therapy 
Factors that affect compliance are complex and involve 
psychological, social and medical issues, all of which may 
alter the patients’ perception of the benefits of compliance 
with their recommended treatment regimen. Social and 
cultural factors, such as socioeconomic status, level of 
education, smoking and alcohol intake, and health belief 
issues will be discussed in a separate article. 
DOSING FREQUENCY 
Rand et al. (29) examined the relationship between self- Increased dosing frequency has been associated with 
reported compliance and objectively measured inhaler decreased adherence to the treatment regimen across a 
usage among a sample of patients with chronic obstructive range of different diseases and therapies (30). For example, 
pulmonary disease. An electronic inhaler timer device one study examining compliance with inhaler medication 
containing either ipratropium bromide or placebo was (using an electronic timer) in 14 children with asthma found 
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prescribed to be taken as two inhalations three times daily 
for 4 months. Compliance was recorded by self-reporting 
(n=95) and change in canister weight (n=70), and 
compared with the electronic recordings of the date and 
time of each inhaler actuation. Over 70% of the patients 
self-reported using the inhaler as prescribed, while the 
electronic recordings showed that only 15% of the patients 
actually used their inhalers an average of 22.5 times a day. 
Canister weight also over-estimated compliance, as only 
62% of the electronic recordings showed the prescribed two 
actuations per dose. Nearly 14% of patients had over 100 
actuations recorded in a 3-h period, thereby suggesting that 
these patients were deliberately emptying, or ‘dumping’, 
their inhalers so as to appear to be complying with the 
regimen. 
TABLE 2. Studies measuring compliance in asthma patients 
Study (Reference) No. of patients Anti-asthma treatment Objective measurement Compliance 
Chryssidis et al. (21) 114 
Glanz et al. (22) 97 
Harding et al. (23) 47 
James et al. (24) 142 
Kinsman et al. (25) 88 
Lleiger and Jones (26) 100 
Spector et al. (27) 19 
Steenhoek and Palman (28) 467 
Inhaled therapy Canister weighing 103 % Inpatients 
196% Outpatients 
Prednisone (for acute attack) Drug levels in plasma 85% 
All None 55% 
All None 49% 
Inhaled therapy None 61% 
All None 61% 
Inhaled sodium cromoglycate ‘Chronology’ 46% 
Theophylline Drug levels in plasma 95% Inpatients 
67% Outpatients 
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that the actual compliance with twice, three- and four-times 
daily dosing was 71%, 34% and 18%, respectively (31). 
This study also found that at all dosing frequencies 
reported, compliance was considerably higher than re- 
corded compliance. Thus, the more complicated the dosing 
regimen the less compliant the patients were, a finding 
confirmed elsewhere (32). 
ROUTE OF ADMINISTRATION 
A study in 276 asthma patients compared compliance with 
oral (theophylline) and inhaled (corticosteroids and sodium 
cromoglycate) asthma medications using medical records 
and pharmacy data (prescription refill patterns) (33). It was 
found that patients had greater compliance with oral 
theophylline than with either inhaled corticosteroids 
(P < 0.001) or inhaled sodium cromoglycate (P = 0.008) 
(Fig. 1). The same study also found that adolescent patients 
(12-17 years) were considerably less compliant than older 
patients (18-65 years) with inhaled medications (80 vs. 
73%, respectively, for theophylline; 30 vs. 57%, respec- 
tively, for inhaled corticosteroids) (33). 
PATIENT AWARENESS 
There is evidence to suggest that the very act of monitoring 
compliance can improve patient compliance. In a study 
assessing patient compliance with prescribed inhaled 
corticosteroids twice daily for 2-3 weeks (compliance being 
assessed using an electromechanical counter which recorded 
the number of actuations), it was found that when patients 
were not informed that drug use was being monitored there 
was a significant difference between actual and prescribed 
use (P<O.OOl) (34). Overall, compliance by those patients 
not informed about monitoring was 70%; six out of 11 
patients were compliant but five were estimated as taking 
less than 30-51% of the prescribed dose. In contrast, there 




cromoglycate corticosteroid theophylline 
FIG. 1. Patient compliance during treatment with oral 
theophylline, inhaled corticosteroid or inhaled sodium 
cromoglycate. *P-co.01 compared with both inhaled 
corticosteroid and sodium cromoglycate therapy. 
Reproduced with permission (33). 
use when patients were aware that drug use was being 
monitored. Overall compliance was 78%; six patients were 
compliant, two patients took >,70% of the prescribed 
medication and two patients were non-compliant. 
PATIENT FEEDBACK 
There is some evidence that sharing feedback on compli- 
ance with the patients themselves can improve their 
compliance. In the Lung Health Study, a subset of 205 
participants, receiving either ipratropium bromide or 
placebo via a metered-dose inhaler, were divided into two 
groups, one of which received feedback on the data from 
the electronic device recording inhaler usage, while the 
other did not (35). Patients receiving feedback at the follow- 
up visit were significantly more compliant than those who 
did not, when considering the proportion of days adherent 
to the prescribed regimen (60.2 vs. 40.4%; P<O.O002), the 
proportion of correct uses (80.6 vs. 60.3%; P<O.OOOl) and 
the mean number of uses per day (1.95 vs. 1.63; P= 0.003; 
three daily uses were prescribed) (Fig. 2). In addition, 
evidence of dose ‘dumping’ immediately before the follow- 
up visit was found in none of the patients given feedback 
compared with 15% of control patients. 
INHALATION TECHNIQUE 
For bronchodilators, some errors of technique are relatively 
harmless, as a lack of clinical effect will frequently result in 
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Percentage of patients 
FIG. 2. The effect of giving patients feedback on their level 
of compliance using an inhaler containing an electronic 
monitoring device. A total of 205 patients were analysed 
and results expressed as the percentage of days adherent 
to prescribed regimen, the proportion of correct uses and 
patients with mean of > 2 uses per day. *P<O.O05 
compared with control group (35). 0: control; 
a: feedback. 
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patients administering an additional dose. However, 
inhalation technique errors are much more likely to reduce 
the therapeutic benefit of anti-inflammatory drugs because 
their clinical effect is not immediately detectable. Inade- 
quate technique can be very difficult to detect by clinicians. 
The use of an objective measurement of inhalation 
technique (such as actuation being followed by an 
inhalation of at least 50% of the vital capacity) has 
revealed many more cases of inadequate technique than a 
simple inspection of the patient’s use of their inhaler (36). 
The development of dry powder inhalers was partly to 
overcome the difficulty some patients experience when 
using metered-dose inhalers. Many patients find dry 
powder inhalers easier to use, as no co-ordination of device 
actuation and inspiration is required. Some dry powder 
inhalers require the patient to have a high inspiratory flow 
for lung deposition. However, the Diskus@ inhaler, a 
relatively new dry powder inhaler, has been developed to 
deliver a high respirable fraction of drug at relatively lower 
inspiratory flow rates (37). 
PATIENT BELIEFS ABOUT THEIR ILLNESS 
AND TREATMENT 
Research involving a range of illnesses shows that patients 
interpret and evaluate medical advice in the light of their 
own beliefs about their illness and its treatment (38). It 
suggests that non-adherence may arise from potentially 
erroneous beliefs about the nature of illness (e.g. its 
severity, likely duration, causes and consequences) and 
the relative benefits and risks of the treatment (39,40). For 
example, many patients avoid taking prescribed medication 
because of misplaced concerns about potential adverse 
effects or because regular usage is perceived to be 
unnecessary (41). Patients will be more likely to follow 
treatment advice if they perceive this to be a common-sense 
approach to maintain their health and if they have a clear 
understanding of the nature of the illness and the relative 
benefits and risks of the treatment. 
Further research is needed to clarify the role of patients 
perceptions of asthma and its treatment as determinants of 
non-compliance. 
Compliance with combined P-agonist 
and corticosteroid therapy 
It is widely believed that compliance with inhaled corticos- 
teroids is poor because they do not afford the immediate 
symptomatic relief provided by bronchodilatory medica- 
tion. An open, multicentre, parallel-group study compared 
compliance with an inhaled corticosteroid (budesonide), an 
inhaled short-acting P-agonist (terbutaline) and an inhaler 
containing a combination of the two drugs (42). All drugs 
were delivered using a Turbuhaler@ inhaler, and an 
electronic device was used to record the time and date of 
each inhalation. The average compliance was 60-70% with 
little difference between the use of a &agonist or inhaled 
corticosteroid. There was total compliance with prescribed 
medication on 3040% of study days. Surprisingly, 
compliance was no greater in patients using the combined 
inhalers. Similar patterns of compliance during the 
study were observed with both the single inhalers and the 
combined inhaler, namely a high level of initial compliance 
followed by a steady decline that improved after clinic 
visits (43). 
However, a limitation of this study is its use of a short- 
acting P-agonist in combination with a corticosteroid. An 
early report from a study examining repeat prescription 
usage of inhaled corticosteroids in general practice, suggests 
that the addition of a long-acting &agonist to existing 
corticosteroid therapy results in an increase in the propor- 
tion of inhaled corticosteroids prescribed (44). 
Conclusion 
Low rates of compliance with medication pose a major 
challenge to the effective management of most chronic 
illnesses including asthma. The causes of non-compliance 
are complex. Characteristics of the regimen such as dosing 
frequency and route of administration may be important 
contributors to non-compliance but are not the only 
factors. Many patients choose not to use their medication 
as instructed because they perceive it to be unnecessary or 
because of concerns about adverse effects. Thus, there is a 
need for an integrated approach to facilitating compliance 
that addresses the patient’s motivation to follow treatment 
advice as well as their ability to do so. In addition to 
ensuring that the regimen is tailored to the patient’s 
lifestyle, there is a need to provide patients with a clear 
rationale for treatment that is consonant with their 
perceptions of the illness and that addresses any concerns 
about the adverse effects of taking it. 
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